NATIONAL INSTITUTES OF HEALTH
- Country
- 🇺🇸United States
- Ownership
- Subsidiary, Private
- Established
- 1948-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.nidcr.nih.gov
Selumetinib in Treating Patients With Biliary Cancer That Cannot Be Removed By Surgery
- Conditions
- Recurrent Extrahepatic Bile Duct CancerLiver and Intrahepatic Biliary Tract CancerUnresectable Extrahepatic Bile Duct Cancer
- Interventions
- Other: laboratory biomarker analysis
- First Posted Date
- 2007-11-04
- Last Posted Date
- 2016-04-22
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 29
- Registration Number
- NCT00553332
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
🇺🇸Emory University, Atlanta, Georgia, United States
🇺🇸University of Michigan Cancer Center (UMCC) Research Base, Ann Arbor, Michigan, United States
Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer
- Conditions
- Stage III Colon CancerAdenocarcinoma of the ColonStage III Rectal CancerStage IV Rectal CancerAdenocarcinoma of the RectumRecurrent Colon CancerRecurrent Rectal CancerStage IV Colon Cancer
- Interventions
- Biological: pertuzumabBiological: cetuximabOther: immunohistochemistry staining methodOther: fluorescence in situ hybridizationOther: gene expression analysisOther: mutation analysisOther: polymerase chain reactionOther: laboratory biomarker analysis
- First Posted Date
- 2007-10-31
- Last Posted Date
- 2015-03-31
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 17
- Registration Number
- NCT00551421
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Selumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer
- Conditions
- Primary Peritoneal CarcinomaMicropapillary Serous CarcinomaBorderline Ovarian Serous TumorLow Grade Ovarian Serous AdenocarcinomaPrimary Peritoneal Low Grade Serous AdenocarcinomaRecurrent Borderline Ovarian Surface Epithelial-Stromal Tumor
- Interventions
- Other: Laboratory Biomarker AnalysisOther: Pharmacological Study
- First Posted Date
- 2007-10-30
- Last Posted Date
- 2020-12-03
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 52
- Registration Number
- NCT00551070
- Locations
- 🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Stanford Cancer Institute Palo Alto, Palo Alto, California, United States
🇺🇸Hartford Hospital, Hartford, Connecticut, United States
Rituximab Treatment of Focal Segmental Glomerulosclerosis
- First Posted Date
- 2007-10-29
- Last Posted Date
- 2025-05-06
- Target Recruit Count
- 10
- Registration Number
- NCT00550342
- Locations
- 🇺🇸
Indiana University, Indianapolis, Indiana, United States
R-(-)-Gossypol Acetic Acid, Cisplatin, and Etoposide in Treating Patients With Advanced Solid Tumors or Extensive Stage Small Cell Lung Cancer
- Conditions
- Extensive Stage Small Cell Lung CancerUnspecified Adult Solid Tumor, Protocol Specific
- Interventions
- First Posted Date
- 2007-10-16
- Last Posted Date
- 2014-04-02
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 27
- Registration Number
- NCT00544596
- Locations
- 🇺🇸
Sanford Cancer Center-Oncology Clinic, Sioux Falls, South Dakota, United States
🇺🇸Gundersen Lutheran, La Crosse, Wisconsin, United States
🇺🇸UW Health Oncology - 1 South Park, Madison, Wisconsin, United States
Blood Sampling for Research Related to Sickle Cell Disease
- Conditions
- Sickle Cell DiseaseSickle Cell AnemiaSickle Cell Trait
- First Posted Date
- 2007-10-11
- Last Posted Date
- 2025-06-17
- Target Recruit Count
- 250
- Registration Number
- NCT00542230
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Gossypol in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme
- Conditions
- Adult Giant Cell GlioblastomaAdult GlioblastomaAdult GliosarcomaRecurrent Adult Brain Tumor
- Interventions
- Other: laboratory biomarker analysis
- First Posted Date
- 2007-10-08
- Last Posted Date
- 2017-08-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 56
- Registration Number
- NCT00540722
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸Johns Hopkins University, Baltimore, Maryland, United States
Obatoclax and Bortezomib in Treating Patients With Aggressive Relapsed or Recurrent Non-Hodgkin Lymphoma
- Conditions
- Adult Non-Hodgkin LymphomaRecurrent Adult Diffuse Large Cell LymphomaRecurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Grade 3 Follicular LymphomaRecurrent Mantle Cell LymphomaRecurrent Marginal Zone LymphomaRecurrent Small Lymphocytic Lymphoma
- Interventions
- Other: laboratory biomarker analysisOther: pharmacological study
- First Posted Date
- 2007-10-02
- Last Posted Date
- 2015-12-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 18
- Registration Number
- NCT00538187
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
The Stress-Hormone System in Alcohol-Dependent Subjects
- Conditions
- Alcoholism
- First Posted Date
- 2007-09-27
- Last Posted Date
- 2017-07-02
- Target Recruit Count
- 70
- Registration Number
- NCT00536146
- Locations
- 🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇺🇸Veterans Affairs Medical Center at Dallas, Dallas, Texas, United States
Effects of Bariatric Surgery on Insulin
- Conditions
- Gastric BypassWeight LossBariatric SurgeryObesityHyperglycemia
- First Posted Date
- 2007-09-26
- Last Posted Date
- 2019-12-17
- Target Recruit Count
- 28
- Registration Number
- NCT00535600
- Locations
- 🇺🇸
NIDDK, Phoenix, Phoenix, Arizona, United States